<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Recent Developments - Biological Agents]]></title><link>http://www.upmc-biosecurity.org/</link><description><![CDATA[Articles written by Center staff relating to biological agents.]]></description><copyright><![CDATA[Copyright 2009. University of Pittsburgh Medical Center. All rights reserved.]]></copyright><managingEditor><![CDATA[webmaster@upmc-biosecurity.org]]></managingEditor><webmaster><![CDATA[webmaster@upmc-biosecurity.org]]></webmaster><lastBuildDate>Fri, 20 Aug 2010 04:03:07 GMT</lastBuildDate><generator>SiteExecutive v4.1</generator><item><title><![CDATA[Novel Strain of Arenavirus Circulating in South Africa (11-03-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-11-03-novelarenavirussoafrica.html</link><description><![CDATA[Biosecurity Briefing: On October 13, 2008, the World Health Organization (WHO) announced that 4 recent deaths in Zambia and South Africa resulted from infection with a novel strain of Arenavirus.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-11-03-novelarenavirussoafrica.html</guid><pubDate>Mon, 03 Nov 2008 20:58:59 GMT</pubDate></item><item><title><![CDATA[BARDA, NIAID Award Anthrax Monoclonal Antibody Contract; NIAID Awards Botulinum Antitoxin Contract (09-15-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html</link><description><![CDATA[Biosecurity Briefing: On September 3, 2008, Emergent BioSolutions, Inc., announced that it had been awarded a $24.3 million contract to develop its anthrax monoclonal antibody AVP-21D9. The contract was awarded jointly by BARDA and NIAID.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html</guid><pubDate>Tue, 16 Sep 2008 14:32:36 GMT</pubDate></item><item><title><![CDATA[Study Examines Role of Human Migration Patterns in Re-Emergence of Tuberculosis in Beijing (09-08-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-09-08-migrantpoptbbeijing.html</link><description><![CDATA[Biosecurity Briefing: The September 2008 issue of Emerging Infectious Diseases (EID) includes an article regarding tuberculosis cases in Beijing, drawing attention to the contribution of migration patterns to the total disease burden in the city.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-09-08-migrantpoptbbeijing.html</guid><pubDate>Tue, 09 Sep 2008 16:09:32 GMT</pubDate></item><item><title><![CDATA[Large Q Fever Epidemic Ongoing in the Netherlands (08-18-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-08-18-qfevernetherlands.html</link><description><![CDATA[Biosecurity Briefing: On July 31, 2008, Eurosurveillance published a study about an ongoing Q fever outbreak in the Netherlands; as of July 24, 677 cases have been reported this year. In past years, relatively few cases of Q fever were reported.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-08-18-qfevernetherlands.html</guid><pubDate>Mon, 18 Aug 2008 15:06:19 GMT</pubDate></item><item><title><![CDATA[Emergent BioSolutions Wins NIAID Grants, Sanofi to Acquire Acambis (08-04-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-08-04-emergentniaidsanofiacambis.html</link><description><![CDATA[Biosecurity Briefing: Emergent BioSolutions, Inc., announced it has been awarded two grants from NIAID for the development of botulism and next-generation anthrax vaccine candidates. AP reported that sanofi-aventis will acquire vaccine-maker Acambis PLC.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-08-04-emergentniaidsanofiacambis.html</guid><pubDate>Mon, 04 Aug 2008 16:15:47 GMT</pubDate></item><item><title><![CDATA[Plague Bacteria Able to Survive in Soil; More Study Needed to Determine Biodefense, Public Health Implications (06-27-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/plague/2008-06-27-plaguesurvivesoil.html</link><description><![CDATA[Biosecurity Briefing: The journal Emerging Infectious Diseases, published a study that may help "shed light" on the "long standing mysteries of how Yersinia pestis persists during [periods of time between disease outbreaks among animals]."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/plague/2008-06-27-plaguesurvivesoil.html</guid><pubDate>Mon, 30 Jun 2008 14:24:34 GMT</pubDate></item><item><title><![CDATA[CDC Reports Vaccinia Infections among Laboratory Workers, Stresses Importance of Vaccination and Biosafety (04-25-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-cdcrptsinfectionlabwrkrs.html</link><description><![CDATA[Biosecurity Briefing: According to the CDC, state health departments reported a total of five cases of laboratory-acquired vaccinia infection to the CDC between 2005-2007. Vaccinia (VACV) is the live virus component of the smallpox vaccine.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-cdcrptsinfectionlabwrkrs.html</guid><pubDate>Mon, 28 Apr 2008 14:02:55 GMT</pubDate></item><item><title><![CDATA[Acambis Wins USG Contract for Smallpox Vaccine (04-25-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-acambisusgsmallpoxvac.html</link><description><![CDATA[Biosecurity Briefing: Reuters reported that British vaccine developer Acambis won a $425 million, 10-year contract to supply the U.S. govt with 9 million doses of the ACAM2000 smallpox vac. each year for delivery to the Strategic National Stockpile.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-acambisusgsmallpoxvac.html</guid><pubDate>Fri, 25 Apr 2008 20:51:43 GMT</pubDate></item><item><title><![CDATA[Brazil Continues to Struggle with Dengue (04-11-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-04-11-brazilstrugglewithdengue.html</link><description><![CDATA[Biosecurity Briefing: On April 9, 2008, Agence France Presse reported that dengue has infected more than 75,000 in Brazil so far. In Rio de Janeiro, the state hit hardest by the outbreak, 18,000 new infections and 12 deaths were reported in the last week.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-04-11-brazilstrugglewithdengue.html</guid><pubDate>Mon, 14 Apr 2008 15:58:33 GMT</pubDate></item><item><title><![CDATA[Brazil Struggles to Control Dengue Epidemic (03-28-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-03-28-brazilstrugglescntldengue.html</link><description><![CDATA[Biosecurity Briefing: The European Centre for Disease Prevention and Control reported that an ongoing epidemic of dengue fever in Brazil has resulted in 32,000 infections and 49 deaths so far this year, with most cases occurring in Rio de Janeiro.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-03-28-brazilstrugglescntldengue.html</guid><pubDate>Fri, 28 Mar 2008 20:37:35 GMT</pubDate></item><item><title><![CDATA[After Ebola Outbreak, Uganda Looks Back at Challenges (02-29-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-02-29-ebolaugandalookschallenges.html</link><description><![CDATA[Biosecurity Briefing: A series of articles published within the last week provide new insight on the challenges Uganda faced in trying to control a recent outbreak of Ebola.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-02-29-ebolaugandalookschallenges.html</guid><pubDate>Mon, 03 Mar 2008 18:11:40 GMT</pubDate></item><item><title><![CDATA[New WHO Survey Finds Global Increase in Drug-Resistant TB Infections (02-29-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-02-29-whofindsincreasedrugresisttb.html</link><description><![CDATA[Biosecurity Briefing:  On Feb. 26, 2008, the WHO released the Fourth Global Report entitled Anti-Tuberculosis Drug Resistance in the World, which, "presents findings from the largest survey to date on the scale of drug resistance in tuberculosis."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-02-29-whofindsincreasedrugresisttb.html</guid><pubDate>Mon, 03 Mar 2008 17:59:11 GMT</pubDate></item><item><title><![CDATA[Ricin Discovered in Las Vegas Hotel Room; FBI Says Not Linked to Terrorism (02-29-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-02-29-ricininlasvegashotelnotterrorism.html</link><description><![CDATA[Biosecurity Briefing: On Feb. 28, 2008, CNN.com reported that police in Las Vegas, Nevada, are "investigating the discovery of . . . the deadly poison ricin in a hotel room." The FBI told Reuters that this is "not thought to be terrorism related."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-02-29-ricininlasvegashotelnotterrorism.html</guid><pubDate>Mon, 03 Mar 2008 17:36:16 GMT</pubDate></item><item><title><![CDATA[Anthrax Outbreak follows Bird Flu Outbreak in West Bengal (02-15-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-02-15-anthraxbirdflubengal.html</link><description><![CDATA[Biosecurity Briefing: Bans lifted on poultry sales in West Bengal, India, following serious H5N1 flu outbreak in South Asia. Also, anthrax infection was confirmed in cows in West Bengal and two neighboring states.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-02-15-anthraxbirdflubengal.html</guid><pubDate>Tue, 19 Feb 2008 16:27:33 GMT</pubDate></item><item><title><![CDATA[Researchers Concerned about Growing Threat of Plague (01-18-2008)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/plague/2008-01-18-researchconcernplague.html</link><description><![CDATA[Biosecurity Briefing: Several news reports released this week highlighted a study published in the journal PLoS Medicine about the growing threat of plague. Plague is caused by the bacteria Yersinia pestis, and it is carried by rodents.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/plague/2008-01-18-researchconcernplague.html</guid><pubDate>Tue, 22 Jan 2008 14:39:59 GMT</pubDate></item><item><title><![CDATA[DRC Shuts Border with Uganda as Ebola Outbreak Persists (12-14-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2007-12-14-drcshutsborderugandaebola.html</link><description><![CDATA[Biosecurity Briefing: IRIN reported that Uganda's neighbor, the Democratic Republic of the Congo, has "closed the lake and land border with Uganda and shut down two markets as a precautionary measure to prevent the spread of Ebola from its neighbor."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2007-12-14-drcshutsborderugandaebola.html</guid><pubDate>Fri, 14 Dec 2007 20:37:44 GMT</pubDate></item><item><title><![CDATA[Uganda Seeks Coordinated Response to Ebola Outbreak (12-07-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/content/2007-12-07-ugandaseekscoordresponseebola.html</link><description><![CDATA[Biosecurity Briefing: Reuters reported that at least 22 people have died and up to 93 have been infected with Ebola in Uganda as of 12-06-07. This outbreak is believed to be caused by "a previously unrecorded type of Ebola, making it a fifth strain."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/content/2007-12-07-ugandaseekscoordresponseebola.html</guid><pubDate>Fri, 07 Dec 2007 20:11:17 GMT</pubDate></item><item><title><![CDATA[HHS Award Multiple Contracts for Anthrax Countermeasures (09-28-2007)]]></title><link>http://www.upmc-cbn.org/report_archive/2007/09_September_2007/cbnreport_09282007.html</link><description><![CDATA[CBN Report: BARDA awarded contracts for advanced development of anthrax countermeasures Anthim and Valortim. BARDA also awarded a purchase contract for BioThrax anthrax vaccine.]]></description><guid isPermaLink="true">http://www.upmc-cbn.org/report_archive/2007/09_September_2007/cbnreport_09282007.html</guid><pubDate>Mon, 01 Oct 2007 13:32:31 GMT</pubDate></item><item><title><![CDATA[WHO Responds to Ebola Outbreak in the Congo (09-14-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/content/2007-09-14-whoebolaoutbreakcongo.html</link><description><![CDATA[Biosecurity Briefing: WHO issued a report about an outbreak of Ebola hemorrhagic fever in the Democratic Republic of the Congo. As of September 11, WHO was "aware" of 372 suspected cases and 166 deaths suspected to be associated with the outbreak.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/content/2007-09-14-whoebolaoutbreakcongo.html</guid><pubDate>Mon, 17 Sep 2007 15:37:49 GMT</pubDate></item><item><title><![CDATA[House Committee Concerned About Timeline for Acquisition of Anthrax Countermeasures (09-14-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html</link><description><![CDATA[Biosecurity Briefing: The House Committee on Homeland Security expressed disappointment regarding the pace with which the agency has moved toward the development and procurement of a recombinant protective antigen anthrax vaccine.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html</guid><pubDate>Mon, 17 Sep 2007 15:12:49 GMT</pubDate></item><item><title><![CDATA[Fruit Bats Are Likely Reservoir for Marburg Virus (08-24-2007)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2007-08-24-fruitbatsreservoirmarburgvirus.html</link><description><![CDATA[Biosecurity Briefing: On August 22, 2007, scientists published a study in the Journal Public Library of Science (PLoS ONE) on the discovery of a "common species of fruit bat" (Rousettus aegyptiacus) as a natural reservoir for the Marburg virus.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2007-08-24-fruitbatsreservoirmarburgvirus.html</guid><pubDate>Mon, 27 Aug 2007 14:35:15 GMT</pubDate></item><item><title><![CDATA[Study Finds Greater Risks Associated with European Smallpox Vaccine (09-08-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-09-08-risksassociatedeuropeanvacc.html</link><description><![CDATA[Biosecurity Briefing: On August 22, 2006, the journal Public Library of Science (PLoS) Medicine published a study indicating that the European smallpox vaccine may have higher morbidity and mortality to than the U.S. vaccine due to differences in strain.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-09-08-risksassociatedeuropeanvacc.html</guid><pubDate>Fri, 08 Sep 2006 21:06:00 GMT</pubDate></item><item><title><![CDATA[Delays in Anthrax Vaccine Delivery Raise Concerns about BioShield Process (08-18-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-08-18-anthraxvxdeliverydelays.html</link><description><![CDATA[Biosecurity Briefing: The San Jose, CA Mercury News reports recent concerns about delivery of a new anthrax vaccine being developed by VaxGen and funded by the Department of Health and Human Services (HHS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-08-18-anthraxvxdeliverydelays.html</guid><pubDate>Fri, 18 Aug 2006 20:55:00 GMT</pubDate></item><item><title><![CDATA[Recent Discoveries May Lead to New Smallpox Treatment and SARS Vaccine (08-11-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-08-11-recentdiscovsmpxSARS.html</link><description><![CDATA[Biosecurity Briefing: In an August 4 news release, researchers at the University of Pennsylvania School of Medicine announced the discovery of a smallpox virus enzyme which may provide clues to the development of new drugs to target the virus.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-08-11-recentdiscovsmpxSARS.html</guid><pubDate>Fri, 11 Aug 2006 21:05:00 GMT</pubDate></item><item><title><![CDATA[HHS Amends Request for Proposal for Third Generation Smallpox Vaccine (07-28-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-07-28-hhsamendsrfpfor3rdgensmpxvx.html</link><description><![CDATA[Biosecurity Briefing: On July 24, HHS issued an amendment to its request for proposal (RFP) for the acquisition of third generation smallpox vaccine based on modified vaccinia Ankara (MVA) for the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-07-28-hhsamendsrfpfor3rdgensmpxvx.html</guid><pubDate>Fri, 28 Jul 2006 21:04:00 GMT</pubDate></item><item><title><![CDATA[HHS Buys Additional Anthrax Therapeutic for the SNS (07-28-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-07-28-hhsbuysaddlanthxtherapforsns.html</link><description><![CDATA[Biosecurity Briefing: On July 28, HHS announced that it had awarded a $143,833,719 contract to Cangene Corporation (Cangene) for the purchase of 10,000 therapeutic courses of Anthrax Immune Globulin (AIG) for the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-07-28-hhsbuysaddlanthxtherapforsns.html</guid><pubDate>Fri, 28 Jul 2006 20:54:00 GMT</pubDate></item><item><title><![CDATA[HHS Purchases Anthrax Therapeutic for the SNS; Development of Additional Candidate Anthrax Therapeutics Continues (06-23-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-23-hhspurchasesanthraxtherapeuticforSNS.html</link><description><![CDATA[Biosecurity Briefing: On June 20, the U.S. Department of Health and Human Services (HHS) announced that it has exercised the option under its contract with Human Genome Sciences, Inc. (HGS) to purchase ABthraxTM for the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-23-hhspurchasesanthraxtherapeuticforSNS.html</guid><pubDate>Fri, 23 Jun 2006 20:53:00 GMT</pubDate></item><item><title><![CDATA[New Anthrax Vaccine with Improved Stability Sought (06-19-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-19-newnanthraxvaccinewithimprovedstabilitysought.html</link><description><![CDATA[Biosecurity Briefing: On June 12, Avecia Biotechnology announced that it had received a $3.9 million grant from the U.S. National Institute of Allergy and Infectious Diseases to develop an anthrax vaccine with "improved stability."]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-06-19-newnanthraxvaccinewithimprovedstabilitysought.html</guid><pubDate>Mon, 19 Jun 2006 20:53:00 GMT</pubDate></item><item><title><![CDATA[HHS Buys Botulism Antitoxin for SNS (06-02-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/botulism/2006-06-02-hhsantitoxin.html</link><description><![CDATA[Biosecurity Briefing: On June 1, HHS announced that it has awarded a 5-year, $362,641,105 contract to Cangene Corporation for the delivery of 200,000 doses of Heptavalent Botulism Antitoxin to the Strategic National Stockpile (SNS).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/botulism/2006-06-02-hhsantitoxin.html</guid><pubDate>Fri, 02 Jun 2006 20:59:00 GMT</pubDate></item><item><title><![CDATA[Experimental Marburg Virus Vaccine May Confer Protection against Disease when Administered Post-Exposure (05-01-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2006-05-01-experimentalmarburgvaxmayco.html</link><description><![CDATA[Biosecurity Briefing: A study published April 27 by the journal Lancet found that an experimental vaccine against Marburg haemorrhagic fever may protect against disease when administered after exposure to Marburg virus.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/viral_hemorrhagic_fevers/2006-05-01-experimentalmarburgvaxmayco.html</guid><pubDate>Mon, 01 May 2006 21:08:00 GMT</pubDate></item><item><title><![CDATA[FDA Issues Warning to VaxGen Regarding its Anthrax Vaccine (03-31-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-fdaissueswarningtovaxgenreg.html</link><description><![CDATA[Biosecurity Briefing: On April 4, the USDA's Office of Compliance and Biologics Quality (OCBQ) made public a warning letter it sent to VaxGen, Inc. on March 24, 2006, regarding VaxGen's candidate anthrax vaccine (rPA102).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-fdaissueswarningtovaxgenreg.html</guid><pubDate>Fri, 31 Mar 2006 20:52:00 GMT</pubDate></item><item><title><![CDATA[Pentagon Releases Report on Response to March 2005 Anthrax Incidents (03-31-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-pentagonreleasesreportonmar.html</link><description><![CDATA[Biosecurity Briefing: According to a March 24 Department of Defense (DoD) press release, the RAND Corporation delivered an assessment to the Pentagon on the department's response to three suspected anthrax incidents that occurred in March 2005.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-31-pentagonreleasesreportonmar.html</guid><pubDate>Fri, 31 Mar 2006 20:52:00 GMT</pubDate></item><item><title><![CDATA[VaxGen Responds to Concerns About its Anthrax Vaccine (03-24-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-24-vaxgenrespondstoconcernsabo.html</link><description><![CDATA[Biosecurity Briefing: On March 17, VaxGen responded to a recent Washington Post report that VaxGen has encountered problems with its anthrax vaccine, rPA102, that may delay its delivery to the government for the Strategic National Stockpile.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-24-vaxgenrespondstoconcernsabo.html</guid><pubDate>Fri, 24 Mar 2006 20:51:00 GMT</pubDate></item><item><title><![CDATA[Candidate Anthrax Treatment Receives Orphan Drug Designation (03-10-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-10-candidateanthraxtrtmtgetsor.html</link><description><![CDATA[Biosecurity Briefing: On March 6, Medarex, Inc. and PharmAthene, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to Valortim™ (MDX- 1303).]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2006-03-10-candidateanthraxtrtmtgetsor.html</guid><pubDate>Fri, 10 Mar 2006 20:50:00 GMT</pubDate></item><item><title><![CDATA[Progress on Development of 3rd Generation Smallpox Vaccines (03-03-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-03-03-progressondevelof3rdgensmal.html</link><description><![CDATA[Biosecurity Briefing: Among the abstracts presented at the ASM Biodefense Research Meeting were several pertaining to the development of potentially safer smallpox vaccines]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-03-03-progressondevelof3rdgensmal.html</guid><pubDate>Fri, 03 Mar 2006 21:03:00 GMT</pubDate></item><item><title><![CDATA[Liability Protection Extended for National Smallpox Vaccination Program (02-03-2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-02-03-liabilityprotectionenabledf.html</link><description><![CDATA[Biosecurity Briefing: On January 24, HHS issued an amendment extending the January 24, 2003 Declaration Regarding Administration of Smallpox Countermeasures.]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-02-03-liabilityprotectionenabledf.html</guid><pubDate>Fri, 03 Feb 2006 21:02:00 GMT</pubDate></item><item><title><![CDATA[Potential Treatment Identified for Complications from Smallpox Vaccination Might Also Hold Promise as a Therapeutic (01.27.2006)]]></title><link>http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-01-27-potentialtrtmtholdstherapeu.html</link><description><![CDATA[]]></description><guid isPermaLink="true">http://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/smallpox/2006-01-27-potentialtrtmtholdstherapeu.html</guid><pubDate>Fri, 27 Jan 2006 21:02:00 GMT</pubDate></item></channel></rss>
